Total operating expenses were $3.34m for third quarter 2011, compared to $10.25m for the same period in 2010. Total other income was $2.64m for third quarter 2011, compared to $2.33m for the same period in 2010.

The company posted a comprehensive loss of $0.71m for third quarter 2011, compared to $7.93m for the same period in 2010.

For the nine months ended September 30, 2011, net loss was $17.17m, compared to $19.71m for the same period in 2010. Total operating expenses were $14.78m, compared to $19.26m for the same period in 2010.

Total other expense was $2.39m for the nine months of 2011, compared to $0.45m for the same period in 2010. Comprehensive loss was $17.15m, compared to $19.72m for the same period in 2010.

As of September 30, 2011, the company had cash, cash equivalents and available-for-sale securities of $4.6m. Cash used in operations was $6m for the three months ended September 30, 2011.

Steven Deitcher, president and CEO of company, said: "In the third quarter of 2011, we achieved two significant accomplishments: the acceptance for filing of our NDA seeking accelerated approval of Marqibo and the Special Protocol Assessment agreement for our Phase 3 confirmatory study, the HALLMARQ Trial.

"During the next several months leading up to our PDUFA date of May 13, 2012, we will be focused on preparing for an Oncology Drug Advisory Committee (ODAC) meeting, preparing for clinical and manufacturing pre-approval inspections, and initiating the HALLMARQ Trial. Our team is more committed than ever to our quest for FDA approval of Marqibo."

Will the company post net income in Q4?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.